MGMT and neoplasm: • Retrospective• Relatively small sample size• No data on steroid use, MGMT promoter methylation status, and IDH mutation status (patients diagnosed between 2004 and 2009)• Neutrophil and lymphocyte counts in isolation were not prognostic• Multivariate analysis adjusted for age, gender, ECOG performance status, extent of resection, tumor location, full Stupp protocol, and second line therapy